N-(4-Amino-6-phenyl-1,3,5-triazin-2-yl)-benzamid | 27374-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-Amino-6-phenyl-1,3,5-triazin-2-yl)-benzamid
• 英文别名: N-(4-amino-6-phenyl-1,3,5-triazin-2-yl)benzamide
• CAS: 27374-29-4
• 化学式: C₁₆H₁₃N₅O
• 分子量: 291.312
• InChiKey: LYYFYMVOLZLJJM-UHFFFAOYSA-N

物化性质

• 熔点：
  230 °C
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  双胍 、 安息香精油 在 氧气 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以24%的产率得到N-(4-Amino-6-phenyl-1,3,5-triazin-2-yl)-benzamid
  参考文献：
  名称：

  �ber Reaktionen von Alkylbiguaniden mit Benzoin beimpH der Biguanidbasen

  摘要：

  Alkylbiguanides 2 a-e react with benzoin (1) at the pH of the base in different ways. 1 undergoes in presence of 2 a, c oxidation to benzoic acid which reacts with the bases 2 a, c to yield 4-phenyl-1,3,5-triazinamines 3 c, 4 c; in presence of 2 b 1 is transformed to benzil, which reacts with 2 b under rearrangement to yield 1-(4-oxo-5,5-diphenyl-2-imidazolin-2-yl)-3,3-dimethylguanidine (5 b). However, the cycloalkylbiguanides 2 d, e react in presence of nitrogen as well as oxygen with 1 to yield piperidine-1-[N-(4,5-diphenylimidazol-2-yl)-carboxamidine] (7 d), resp. morpholine-4-[N-(4,5-diphenylimidazol-2-yl)-carboxamidine] (7 e). The structure of 7 e was established by means of an X-ray structure analysis. All proton- and carbon resonances were assigned on the basis of 2-dimensional NMR data.

  DOI：

  10.1007/bf00811115

文献信息

• Pyrimidine Derivatives As HSP90 Inhibitors
  申请人：Chessari Gianni

  公开号：US20090215777A1

  公开（公告）日：2009-08-27

  The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR 3 ; R 1 is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of which up to two ring members may be heteroatoms selected from N, O and S and the remainder are carbon atoms, the carbocyclic or heterocyclic ring being optionally substituted by one or more substituent groups independently selected from R 10 ; and R 2 , R 3 and R 10 are as defined in the claims.

  该发明提供了一种化合物，用作Hsp90的抑制剂，该化合物具有以下式（I）：或其盐、互变异构体、溶剂合物或N-氧化物；其中：A为N或CR基团；R1为由5至10个环成员组成的单环或双环碳环或杂环，其中最多两个环成员可以是从N、O和S中选择的杂原子，其余为碳原子，碳环或杂环可以选择地被一个或多个取代基独立地选择自R10的取代基取代；而R2、R3和R10如权利要求中所定义。
• ANTICANCER COMPOSITION AND COMPOUND
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0563386A1

  公开（公告）日：1993-10-06

  An anticancer composition containing a compound represented by general formula (I) or a pharmacologically acceptable acid addition salt thereof. In formula (I), R¹⁰ and R²⁰ may be the same or different from each other and each represents hydrogen, halogen, amino, aralkylamino, nitro, lower alkyl, lower alkoxy, lower alkoxyalkoxy, lower aralkyloxy or acyl; R³⁰ and R⁴⁰ may be the same or different from each other and each represents hydrogen, nicotinoyl, benzoyl or lower alkoxy; and n represents 0 or 1.

  一种抗癌组合物，含有通式(I)代表的化合物或其药理学上可接受的酸加成盐。在式 (I) 中，R¹⁰ 和 R²⁰ 可以彼此相同或不同，各自代表氢、卤素、氨基、烷基氨基、硝基、低级烷基、低级烷氧基、低级烷氧基烷氧基、低级芳氧基或酰基；R³⁰ 和 R⁴⁰ 可以彼此相同或不同，各自代表氢、烟酰基、苯甲酰基或低级烷氧基；n 代表 0 或 1。
• PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS
  申请人：Astex Therapeutics Limited

  公开号：EP2049497A2

  公开（公告）日：2009-04-22
• AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：EP3197884A1

  公开（公告）日：2017-08-02
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2006123165A2

  公开（公告）日：2006-11-23

  [EN] The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR³; R¹ is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of which up to two ring members may be heteroatoms selected from N, O and S and the remainder are carbon atoms, the carbocyclic or heterocyclic ring being optionally substituted by one or more substituent groups independently selected from R¹⁰; and R², R³ and R¹⁰ are as defined in the claims.
  [FR] La présente invention concerne un composé inhibiteur de Hsp90 représenté par la formule générale (I), l'un de ses sels, tautomères, solvats ou N-oxydes. Dans cette formule, A est N ou un groupe CR³. R¹ est un noyau monocyclique ou bicyclique, carbocyclique ou hétérocyclique portant de 5 à 10 segments dont deux au maximum peuvent être hétéroatomes choisis parmi N, O et S, le reste étant des atomes de carbone. Le noyau carbocyclique ou hétérocyclique est éventuellement substitué par un ou plusieurs groupes substituants choisis indépendamment parmi R¹⁰. R², R³ et R¹⁰ sont tels que définis dans les revendications.